J Rivalan
Overview
Explore the profile of J Rivalan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gatault P, Kamar N, Buchler M, Colosio C, Bertrand D, Durrbach A, et al.
Am J Transplant
. 2016 Nov;
17(5):1370-1379.
PMID: 27862923
The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety of two different doses of extended-release tacrolimus (TacER) in kidney transplant recipients (KTRs) between 4 and...
2.
Videt-Gibou D, Belliard S, Rivalan J, Menard D, Edan G
Rev Neurol (Paris)
. 2010 May;
166(6-7):639-43.
PMID: 20466396
Introduction: The hematological manifestations of acquired copper deficiency are well known. But the neurological manifestations have only been recognised in the past few years. The most common neurological manifestation in...
3.
Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression
Mourad G, Garrigue V, Squifflet J, Besse T, Berthoux F, Alamartine E, et al.
Transplantation
. 2001 Oct;
72(6):1050-5.
PMID: 11579299
Background: The aim of this study was to compare the efficacy and safety of induction treatment with antithymocyte globulins (ATG) followed by tacrolimus therapy with immediate tacrolimus therapy in renal...
4.
Rivalan J
Presse Med
. 2001 Oct;
30(24 Pt 2):38-40.
PMID: 11577587
MONOCLONAL ANTIBODIES: Monoclonal antibodies have been humanized to improve their duration of action and their tolerance. Lymphocyte-depleting humanized anti-CD3 antibodies are globally well tolerated. Coupled with an immunotoxin, Campath 1H,...
5.
Bensalah K, Guille F, Rivalan J, Joyeux V, Gie S, Laruelle E, et al.
Prog Urol
. 2001 Jun;
11(2):231-4.
PMID: 11400483
Introduction: The objective of this study was to assess the long-term outcome of AV shunts in renal transplant recipients, to discuss mechanisms affecting their functioning and the surgical strategy designed...
6.
Garin E, Devillers A, Rivalan J, Girault S, Moisan A, Le Cloirec J, et al.
Nucl Med Commun
. 2000 Mar;
21(1):77-81.
PMID: 10717906
Routine 99Tcm-dimercaptosuccinic acid (DMSA) scintigraphy was performed in a series of 24 kidney transplant recipients with impaired renal function. Diagnostic findings on planar and tomoscintigraphic acquisitions obtained 3 and 4...
7.
Furby A, Mourtada R, Charasse C, Rivalan J, Messner M, Leroy J
Rev Neurol (Paris)
. 2000 Feb;
156(1):62-4.
PMID: 10693261
From the age of 31 a patient began to suffer from recurrent calcium oxalate urolithiasis. Liver biopsy showed a decrease in catalytic activity of the hepatic peroxisomal enzyme alanine: glyoxilate...
8.
Chevet D, Rivalan J, Rebibou J, Michel F, Guignier F
Nephron
. 1996 Jan;
73(3):495.
PMID: 8832620
No abstract available.
9.
Benkalfate L, Zein K, Le Gall F, Chevrant-Breton J, Rivalan J, Le Pogamp P
Ann Dermatol Venereol
. 1995 Jan;
122(11-12):789-92.
PMID: 8729828
Introduction: Calcinosis cutis is classically described in patients presenting chronic renal failure with secondary hyperparathyroidism. There are three clinical types described in the literature: cutaneous necrosis (secondary to vascular calcification),...
10.
Islam M, Bard J, Le Pogamp P, Leglise D, Bourbigot B, Rivalan J, et al.
Nephrol Dial Transplant
. 1994 Jan;
9(3):332-3.
PMID: 8052449
No abstract available.